Traws Pharma Seeks Stockholder Approval for 1-for-8 to 1-for-15 Reverse Split to Regain Nasdaq Compliance
TRAW is trading near its 52-week low of $0.43 (12% above the low) on light trading volume (0.2× avg).
Summary
Traws Pharma is asking stockholders to approve a reverse stock split between 1-for-8 and 1-for-15 to regain Nasdaq's $1.00 minimum bid price compliance after receiving a delisting notice in July.
Key Events · Corporate Governance and Compliance · TRAW
-
Reverse Split Authorization Proposed
Board approved a reverse stock split authorization on October 6, 2026, with a ratio range of 1-for-8 to 1-for-15, to be determined by the board within twelve months of stockholder approval.
-
Nasdaq Delisting Risk
Company received a Nasdaq deficiency letter on July 29, 2026, for trading below $1.00 for 30 consecutive business days, with a compliance deadline of January 25, 2027.
-
Share Count and Warrant Overhang
15,368,277 common shares outstanding as of September 30, 2026, plus 29,914,595 warrants subject to adjustment — the split will proportionally reduce both while leaving 250 million authorized shares unchanged.
-
Board Discretion and Timing
Board may implement the split at any ratio within the approved range within twelve months, or abandon it entirely; expects to implement shortly after stockholder approval given current price levels.
Analysis · TRAW · Life Sciences
Traws Pharma's board approved a reverse stock split authorization on October 6, 2026, asking stockholders to approve a ratio between 1-for-8 and 1-for-15. The company received a Nasdaq delisting notice on July 29, 2026, after its stock traded below $1.00 for 30 consecutive business days, and has until January 25, 2027 to regain compliance. With the stock at $0.48 today, the reverse split is the primary mechanism to lift the price above the $1.00 minimum bid requirement. The filing also reveals 15,368,277 common shares outstanding and 29,914,595 warrants, meaning the split will proportionally reduce both while leaving the 250 million authorized shares unchanged — effectively increasing the headroom for future dilution. The board has full discretion to implement the split at any ratio within the approved range within twelve months, or abandon it entirely.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRAW was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.43 to $3.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.